Strengthening the influenza vaccine virus selection and development process. Report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014.

Vaccine

Volumn 33, Issue 36, 2015, Pages 4368-4382

  Ampofo, William K ^a   Azziz Baumgartner, Eduardo ^b   Bashir, Uzma ^c   Cox, Nancy J ^b   Fasce, Rodrigo ^d   Giovanni, Maria ^e   Grohmann, Gary ^f   Huang, Sue ^g   Katz, Jackie ^b   Mironenko, Alla ^h   Mokhtari Azad, Talat ⁱ   Sasono, Pretty Multihartina ^e   Rahman, Mahmudur ^j   Sawanpanyalert, Pathom ^e   Siqueira, Marilda ^k   Waddell, Anthony L ^l   Waiboci, Lillian ^m   Wood, John ⁿ   Zhang, Wenqing ^o   Ziegler, Thedi ^p  

^a University of Ghana   (Ghana)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONAL INSTITUTE OF HEALTH   (Pakistan)

^d INSTITUTO DE SALUD PÚBLICA DE CHILE   (Chile)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f Therapeutics Goods Administration   (Australia)

^g National Influenza Center   (New Zealand)

^h Reference Influenza Laboratory   (Ukraine)

ⁱ National Influenza Center   (Iran)

^j Institute of Epidemiology Disease Control and Research   (Bangladesh)

^k INSTITUTO OSWALDO CRUZ   (Brazil)

^l Rio de Janeiro ^*  (United Kingdom)

^m Centers for Disease Control and Prevention Kenya   (Kenya)

ⁿ NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^o WORLD HEALTH ORGANIZATION   (Switzerland)

^p National Influenza Center   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE;

DISEASE SURVEILLANCE; DRUG BIOAVAILABILITY; DRUG MANUFACTURE; FLU LIKE SYNDROME; GENETIC VARIABILITY; HEALTH CARE AVAILABILITY; HUMAN; INFLUENZA VACCINATION; INFLUENZA VIRUS; NEXT GENERATION SEQUENCING; NONHUMAN; NOTE; PANDEMIC INFLUENZA; PREVENTION AND CONTROL; PRIORITY JOURNAL; SEASONAL INFLUENZA; SEASONAL VARIATION; VACCINE PRODUCTION; VIRUS CHARACTERIZATION; VIRUS TRANSMISSION; EPIDEMIOLOGICAL MONITORING; IMMUNOLOGY; INFLUENZA, HUMAN; INTERNATIONAL COOPERATION; ISOLATION AND PURIFICATION; PHARMACEUTICS; WORLD HEALTH ORGANIZATION;

EPIDEMIOLOGICAL MONITORING; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERNATIONAL COOPERATION; TECHNOLOGY, PHARMACEUTICAL; WORLD HEALTH ORGANIZATION;

EID: 84939569063     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.06.090     Document Type: Note

References (12)

1. Improving influenza vaccine virus selection. Report of a WHO informal consultation. Influ Other Respir Viruses 2012, 6(2):142-152. WHO Writing Group, [http://onlinelibrary.wiley.com/doi/10.1111/j.1750-2659.2011.00277.x/abstract, accessed 26.05.14, WHO headquarters, Geneva, Switzerland, 14-16 June 2010].
2. Strengthening the influenza vaccine virus selection and development process. Outcome of the 2nd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection. Vaccine 2013, 31(32):3209-3221. WHO Writing Group, [http://www.sciencedirect.com/science/article/pii/S0264410X13006373, accessed 26.05.14, Centre International de Conférences (CICG), Geneva, Switzerland, 7-9 December 2011].
3. Selection of clinical specimens for virus isolation and of viruses for shipment from National Influenza Centres to WHO Collaborating Centres. World Health Organization, http://www.who.int/influenza/gisrs_laboratory/national_influenza_centres/20101206_specimens_selected_for_virus_isolation_and_shipment.pdf?ua=1 2010 [accessed 29.05.14
4. Azziz Baumgartner E., Dao C.N., Nasreen S., Bhuiyan M.U., Mah-E-Muneer S., Al Mamun A., et al. Seasonality, timing, and climate drivers of influenza activity worldwide. J Infect Dis 2012, 206(6):838-846. [http://www.ncbi.nlm.nih.gov/pubmed/22829641, accessed 01.11.14].
5. De Mello W.A., De Paiva T.M., Ishida M.A., Benega M.A., Dos Santos M.C., Viboud C., et al. The dilemma of influenza vaccine recommendations when applied to the tropics: the Brazilian case examined under alternative scenarios. PLoS One 2009, 4(4):e5095. [http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0005095;jsessionid=4FD9FB6C0971EA38375DDE5AA427D08E, accessed 01.06.14].
6. Saha S., Chadha M., Al Mamun A., Rahman M., Sturm-Ramirez K., Chittaganpitch M., et al. Influenza seasonality and vaccination timing in tropical and subtropical areas of southern and south-eastern Asia. Bull World Health Organ 2014, 92(5):318-330. http://www.who.int/bulletin/volumes/92/5/13-124412.pdf, accessed 01.06.14
7. Legrand J., Vergu E., Flahault A. Real time monitoring of the influenza vaccine field effectiveness. Vaccine 2006, 24(44-46):6605-6611. [http://www.ncbi.nlm.nih.gov/pubmed/16806607, accessed 01.06.14].
8. Smith D.R., Lapedes A.S., de Jong J.C., Bestebroer T.M., Rimmelzwaan G.F., Osterhaus A.D., et al. Mapping the antigenic and genetic evolution of influenza virus. Science 2004, 305(5682):371-376. [http://www.sciencemag.org/content/305/5682/371, accessed 01.06.14].
9. WHO Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza. Geneva: World Health Organization, 〈http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf 2011 [accessed 26.05.14].
10. Ducatez M.F., Bahl J., Griffin Y., Stigger-Rosser E., Franks J., Barman S., et al. Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development. Proc Natl Acad Sci 2011, 108(1):349-354. [http://www.pnas.org/content/108/1/349, accessed 21.06.14].
11. Pan W., Dong Z., Meng W., Zhang W., Li T., Li C., et al. Improvement of influenza vaccine strain A/Vietnam/1194/2004 (H5N1) growth with the neuraminidase packaging sequence from A/Puerto Rico/8/34. Hum Vaccines Immunother 2012, 8(2):252-259. [http://www.ncbi.nlm.nih.gov/pubmed/22426370, accessed 21.06.2014].
12. Franco L.M., Bucasas K.L., Wells J.M., Niño D., Wang X., Zapata G.E., et al. Integrative genomic analysis of the human immune response to influenza vaccination. elife 2013, 2(June):e00299. http://elifesciences.org/content/2/e00299 [accessed 26.05.14].